Gilead Sciences (GILD) Tops Q2 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Gilead Sciences (GILD) PT Raised to $85 at Morgan Stanley
July 26, 2018 8:53 AM EDTMorgan Stanley raised its price target on Gilead Sciences (NASDAQ: GILD) to $85.00 (from $81.00) while maintaining a Equalweight rating.
... MoreGilead Sciences (GILD) PT Raised to $90 at RBC Capital
July 26, 2018 7:58 AM EDTRBC Capital raised its price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $87.00) while maintaining an Outperform rating following results.
Analyst Brian Abraham commented, "With strong HIV sales and HCV stabilizing, GILD seems to be tracking towards steadier earnings base upon which... More
